Oculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery to the eye.
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.
Founders: Einar Stefansson, MD, PhD and Thorsteinn Loftsson, PhD
CEO: Pall Ragnar Johnnesson
CCO: (Regulatory and Clinical) Gudrun Marta Asgrimsdottir, MSc
CSO: Thorsteinn Loftsson, PhD
Please click here for.
Please click here for clinical trial information.